These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35014922)

  • 1. Evaluating upadacitinib for the treatment of psoriatic arthritis.
    Akpabio A; Adebajo A
    Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib for the treatment of adult patients with active psoriatic arthritis.
    Marchesoni A; Citriniti G; Girolimetto N; Possemato N; Salvarani C
    Expert Rev Clin Immunol; 2024 May; 20(5):423-434. PubMed ID: 38155531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of upadacitinib in the treatment of psoriatic arthritis.
    Ross Y; Magrey M
    Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
    N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
    Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
    Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib in nail psoriasis: a case report.
    Wang N; Yang Q; Liu Y; Liu H
    J Dermatolog Treat; 2023 Dec; 34(1):2246604. PubMed ID: 37661936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
    Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
    Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Mease P; Setty A; Papp K; Van den Bosch F; Tsuji S; Keiserman M; Carter K; Li Y; McCaskill R; McDearmon-Blondell E; Wung P; Tillett W
    Clin Exp Rheumatol; 2023 Nov; 41(11):2286-2297. PubMed ID: 37404160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib tartrate in rheumatoid arthritis.
    Stamatis P; Bogdanos DP; Sakkas LI
    Drugs Today (Barc); 2020 Nov; 56(11):723-732. PubMed ID: 33332480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
    Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
    Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
    Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.